Translation and Validation of the Performance Oriented Mobility Assessment (Poma) Scale Into Urdu Version

April 28, 2022 updated by: Riphah International University

Cross-cultural Translation and Validation of the Performance Oriented Mobility Assessment (Poma) Scale Into Urdu Version

The aim of this study is to translate the original English version POMA scale into Urdu and also determine cultural adaptation to establish its validity and reliability. This study also aims to correlate Performance oriented Mobility Assessment (POMA) scales with time up and go test in elderly population.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Among older persons, age-related impairments cause loss of postural control and balance that result in pain, independency and disability. One of the most common geriatric syndromes and most serious health issue threatening the independency of older persons is fall. The impact of these fall-related injuries on older person, families and societies and its fruitful intervention has made this issue important worldwide. Approximately 28-35% of people aged 65 years and 32-42% of aged 70 years' experience falls annually and 10% suffer serious injury such as, fracture, severe head trauma and joint dislocation. The incidence rate of fall is higher in hospitalized and residents of nursing home. It rises from middle age and peaks in person above 80 years. The risk factors associated with falls are, lower extremity muscle weakness, gait or balance deficits, use of an assistive device, cognitive impairment, visual deficit, arthritis and impaired activities of daily living . Different scales and tests are used for risk factors for falls, balance and mobility such as Berg Balance Scale, Time up and go test and dynamic gait index and Fullerton Advanced Balance Scale. One of these scales Performance-Oriented Mobility Assessment (POMA) scale. POMA scale has acceptable reliability and validity as compared to FRT and TUG in elderly. The advantages of this scale are; applicability, low cost, easy to administer, no equipment is needed other than a standard chair and stopwatch, evaluates functional activities and assesses both balance (POMA-B) and gait components (POMA-G)Originally POMA scale was used to assess risk of fall in institutionalized populations but later on used as an assessment tool for mobility and determine effects of interventions.

The POMA has found to be widely used in patients who have dynamic and reactive balance deficits. It comprises 16 items (9 balance and 7 gait related). Total time taken for administration is approximately 10 minutes and total score is 28; 16 is balance and 12 is gait score. Some Items are scored dichotomously (can/cannot perform) and others are scored 0, 1 or 2 points for quality of performance. The higher scores show low fall risk and better balance while lower score predicts poorer balance and greater risk of fall. The score 19-24/28 indicates moderate risk for falling while score <19 indicates a "high" risk for falling.

Study Type

Observational

Enrollment (Actual)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
      • Rawalpindi, Pakistan, 46000
        • Misbah Ghous

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Performance-oriented Mobility Assessment (POMA) is one of the functional measures used to evaluate balance, gait, and fall risk in the elderly.

Description

Inclusion Criteria:

  • The sample will be assessed a cognition evaluation through the mini-mental test
  • Any present or previous history of vertigo since last 6 months

Exclusion Criteria:

  • Patients with any neurological disorder,
  • previous orthopedic surgery within last 6 months,
  • bedridden,
  • wearing any prosthesis, and illiteracy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Performance oriented mobility Assessment scale
Time Frame: 1 time assessment of mobility and balance (approximately 10 minutes)
Performance oriented mobility Assessment scale is used to assess risk of fall in institutionalized populations but later on used as an assessment tool for mobility and balance assessment. Total time taken for administration is approximately 10 minutes and total score is 28; 16 is balance and 12 is gait score
1 time assessment of mobility and balance (approximately 10 minutes)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Riphah International University

Investigators

  • Principal Investigator: Misbah ghous, MS, Riphah International University Islamabad

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2021

Primary Completion (Actual)

March 31, 2022

Study Completion (Actual)

March 31, 2022

Study Registration Dates

First Submitted

October 19, 2021

First Submitted That Met QC Criteria

October 19, 2021

First Posted (Actual)

November 1, 2021

Study Record Updates

Last Update Posted (Actual)

April 29, 2022

Last Update Submitted That Met QC Criteria

April 28, 2022

Last Verified

April 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • REC/00964 Kiran

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fall

Clinical Trials on Tool Translation & Validation study

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe